Trending News Today: Osimertinib Improves Overall Survival in NSCLC with EGFR Mutations

AstraZeneca announced that osimertinib (Tagrisso) improved overall survival (OS) in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations. According to the press release, data from the phase 3 FLAURA trial showed that osimertinib demonstrated a statistically significant and clinically meaningful improvement in OS compared with erlotinib or gefitinib. The FLAURA trial met its primary endpoint in 2017, showing a statistically significant and clinically meaningful improvement in progression-free survival. 
 
A recent study found that pregnant women may be less likely to develop gestational diabetes when switching to a Mediterranean diet from their usual eating habits, Reuters reported. According to the article, the researchers studied 1252 women who were at high risk of developing gestational diabetes during pregnancy and assigned approximately half of the women to a Mediterranean diet. Compared with women who did not change their eating habits, females who switched to the Mediterranean diet were 35% less likely to develop gestational diabetes, the article reported.
 
A new study suggests that second primary cancers (SPCs) may appear more frequently in patients with malignant melanoma if there is a prior family history of cancer, The American Journal of Managed Care reported. According to the article, the study evaluated the relative risks and causes of deaths from SPCs in patients with a malignant melanoma diagnosis between 1958 and 2015. Overall, the study showed that a family history of lung, ovary, kidney, bladder, and skin cancers and leukemia more than doubled the risk of SPC, the article reported


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$